EYPT - Yutiq (for posterior uveitus) finally booking revenues after some effort. Dexycu (for cataract operation inflammation) showing some early signs of life and has the bigger revenue potential.

http://investors.psivida.com/news-releases/ne...th-quarter

Chart>>>>>>

https://stockcharts.com/h-sc/ui?s=EYPT&p=...6576929333